GFAP and myeloid sarcoma: In our study, we confirmed a negative correlation between the serum levels of VitD and the concentrations of GFAP, NF-H and S100B in the CSF patients with MS, which suggests that lower levels of VitD play an unfavorable role in brain injury reflected by higher concentrations of biomarkers of neurodegeneration in the CSF.